相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy.
A. M. Wardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
K. Yong et al.
BRITISH JOURNAL OF CANCER (2016)
Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions
Meining Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
S. Ramalingam et al.
ANNALS OF ONCOLOGY (2015)
P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement
Hee Joung Kim et al.
BMC CANCER (2015)
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Melissa L. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Maximizing the Therapeutic Potential of HSP90 Inhibitors
Lisa M. Butler et al.
MOLECULAR CANCER RESEARCH (2015)
Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery
Celeste B. Greer et al.
CELL REPORTS (2015)
Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer
Andrea Cercek et al.
CLINICAL COLORECTAL CANCER (2014)
Drugging the HDAC6-HSP90 interplay in malignant cells
Oliver H. Kraemer et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
M. A. Dickson et al.
ANNALS OF ONCOLOGY (2013)
TAp73 Protein Stability Is Controlled by Histone Deacetylase 1 via Regulation of Hsp90 Chaperone Function
Jin Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Targeting HSF1 sensitizes cancer cells to HSP90 inhibition
Yaoyu Chen et al.
ONCOTARGET (2013)
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
Komal Jhaveri et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2012)
Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
L. Whitesell et al.
CURRENT MOLECULAR MEDICINE (2012)
Modulation of Histone Deacetylase 6 (HDAC6) Nuclear Import and Tubulin Deacetylase Activity through Acetylation
Yuanjing Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Physical and Functional HAT/HDAC Interplay Regulates Protein Acetylation Balance
Alessia Peserico et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Targeting the dynamic HSP90 complex in cancer
Jane Trepel et al.
NATURE REVIEWS CANCER (2010)
Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells
Nathatie Gaspar et al.
CANCER RESEARCH (2009)
MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
Ann F. Chambers
CANCER RESEARCH (2009)
HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
Rekha Rao et al.
BLOOD (2008)
P-glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response
Andrea K. McCollum et al.
CANCER RESEARCH (2008)
Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin
Joanna L. Holmes et al.
CANCER RESEARCH (2008)
Role of acetylation and extracellular location of heat shock protein 90α in tumor cell invasion
Yonghua Yang et al.
CANCER RESEARCH (2008)
NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis
Suzanne A. Eccles et al.
CANCER RESEARCH (2008)
Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
David B. Solit et al.
CLINICAL CANCER RESEARCH (2008)
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Elisabeth I. Heath et al.
CLINICAL CANCER RESEARCH (2008)
4,5-diarylisoxazole HSP90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer
Paul A. Brough et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
MDA-MB-435 cells are derived from M14 melanoma cells - a loss for breast cancer, but a boon for melanoma research
James M. Rae et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
An acetylation site in the middle domain of Hsp90 regulates chaperone function
Bradley T. Scroggins et al.
MOLECULAR CELL (2007)
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Swee Y. Sharp et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism
Andrea K. McCollum et al.
CANCER RESEARCH (2006)
Negative and positive regulation of gene expression by mouse histone deacetylase 1
Gordin Zupkovitz et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma
Ellen A. Ronnen et al.
INVESTIGATIONAL NEW DRUGS (2006)
Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs
EK Baker et al.
ONCOGENE (2005)
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
SD Dias et al.
CANCER RESEARCH (2005)
Abrogation of heat shock protein 70 induction as a strategy, to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
F Guo et al.
CANCER RESEARCH (2005)
The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line
JT Price et al.
CANCER RESEARCH (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
JJ Kovacs et al.
MOLECULAR CELL (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
Lineage infidelity of MDA-MB-435 cells: Expression of melanocyte proteins in a breast cancer cell line
S Sellappan et al.
CANCER RESEARCH (2004)
Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective
Alison Maloney et al.
CURRENT CANCER DRUG TARGETS (2003)
Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90
WP Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Modulation of Akt kinase activity by binding to Hsp90
S Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Systematic variation in gene expression patterns in human cancer cell lines
DT Ross et al.
NATURE GENETICS (2000)
分享论文
